Fifteen Years of Experience with Intrathecal Autologous Bone Marrow–Derived Cells: Safety, Infection Profile, and Caregiver-Reported Outcomes in CP and ASD | Synapse
March 3, 2026
Fifteen Years of Experience with Intrathecal Autologous Bone Marrow–Derived Cells: Safety, Infection Profile, and Caregiver-Reported Outcomes in CP and ASD
Key Points
Favorable caregiver-reported outcomes were observed over 15 years for participants receiving intrathecal autologous bone marrow-derived cells.
The infection profile indicated a low incidence of complications, enhancing the safety profile of the intervention.
Observational analysis revealed that patients with CP and ASD benefited from these treatments, with caregivers noting improved outcomes.
These findings support potential wider application of intrathecal autologous bone marrow-derived cells, but further studies are warranted.
Like
Bookmark
Share
Like
Bookmark
Share
Cite This Study
Mancias-Guerra et al. (Sun,) studied this question.